l carnitine tmao nature medicine 2013 koeth Gut Microbiota-Derived TMAO: A Causal Factor Promoting Atherosclerotic Cardiovascular Disease? Gut Microbiota-Dependent Marker TMAO in
Gut Microbiota Dependent Marker TMAO in Promoting Cardiovascular Disease: Inflammation Mechanism, Clinical Prognostic, and Potential as a Therapeutic Target PMC Trimethylamine N Oxide and Related Gut Microbe Derived Metabolites and Incident Heart Failure Development in Community Based Populations Circulation: Heart Failure Trimethylamine N Oxide From Gut Microbiota in Chronic Kidney Disease Patients: Focus on Diet Journal of Renal Nutrition Gut Derived Metabolite, Trimethylamine N oxide (TMAO) in Cardio Metabolic Diseases: Detection, Mechanism, and Potential Therapeutics Butyrobetaine is a pro atherogenic intermediate in gut microbial metabolism of L carnitine to TMAO PMC Characterization of TMAO productivity from carnitine challenge facilitates personalized nutrition and microbiome signatures discovery Microbiome Springer Nature Link
Pay in 4 interest-free payments of $5.05 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 2 - Aug 7





